Amgen Challenges Bristol Myers Squibb with Three IPR Petitions on March 01, 2025 Amgen Bristol Myers Squibb cancer IPR PD-1 PD-L1 + PTAB Amgen Bristol Myers Squibb cancer IPR PD-1 PD-L1 PTAB